Amneal Pharmaceuticals, Company Insiders

AMRX Stock  USD 8.27  0.08  0.96%   
Amneal Pharmaceuticals, employs about 7.8 K people. The company is managed by 27 executives with a total tenure of roughly 74 years, averaging almost 2.0 years of service per executive, having 290.74 employees per reported executive. Break down of Amneal Pharmaceuticals,'s management performance can provide insight into the company performance.
Chintu Patel  CEO
Co-Chief Executive Officer, Co-Founder, Director
Chirag Patel  CEO
President, Co-Chief Executive Officer, Co-Founder, Director
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Amneal Pharmaceuticals, Class. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Amneal Pharmaceuticals,'s Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Amneal Pharmaceuticals,'s future performance. Based on our forecasts, it is anticipated that Amneal will maintain a workforce of slightly above 7850 employees by January 2025.
 
Covid

Amneal Pharmaceuticals, Management Team Effectiveness

The company has return on total asset (ROA) of 0.0594 % which means that it generated a profit of $0.0594 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.8577) %, meaning that it created substantial loss on money invested by shareholders. Amneal Pharmaceuticals,'s management efficiency ratios could be used to measure how well Amneal Pharmaceuticals, manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to rise to 0.12 in 2024, despite the fact that Return On Tangible Assets are likely to grow to (0.04). At this time, Amneal Pharmaceuticals,'s Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 933.3 M in 2024, whereas Total Assets are likely to drop slightly above 3.2 B in 2024.
Common Stock Shares Outstanding is likely to drop to about 151.5 M in 2024. Net Loss is likely to rise to about (111.1 M) in 2024

Amneal Pharmaceuticals, Workforce Comparison

Amneal Pharmaceuticals, Class is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 24,409. Amneal Pharmaceuticals, totals roughly 7,850 in number of employees claiming about 32% of equities under Health Care industry.

Amneal Pharmaceuticals, Profit Margins

The company has Profit Margin (PM) of (0.07) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.470.3428
Significantly Up
Slightly volatile

Amneal Pharmaceuticals, Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Amneal Pharmaceuticals, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Amneal Pharmaceuticals,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Amneal Pharmaceuticals, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2024-06-01
1.6364
18
11
 1,097,083 
 756,658 
2024-03-01
0.931
27
29
 7,438,825 
 34,294,566 
2023-12-01
1.0
5
5
 144,003,290 
 144,003,290 
2023-09-01
0.5
1
2
 54,949 
 84,251 
2023-06-01
1.8
18
10
 1,414,828 
 707,741 
2023-03-01
1.0476
22
21
 4,180,485 
 547,267 
2022-06-01
1.3571
19
14
 1,017,786 
 366,874 
2022-03-01
0.8333
10
12
 1,057,482 
 214,249 
2021-12-01
2.0
2
1
 3,123,298 
 2,000 
2021-06-01
1.3571
19
14
 742,466 
 463,249 
2021-03-01
0.9
9
10
 851,626 
 201,665 
2020-12-01
1.0
3
3
 22,566 
 22,566 
2020-09-01
3.0
3
1
 125,130 
 27,923 
2020-06-01
1.8889
17
9
 484,959 
 63,072 
2020-03-01
1.75
14
8
 1,632,158 
 98,193 
2019-12-01
1.625
13
8
 13,854,248 
 26,633,597 
2019-06-01
1.625
26
16
 356,349 
 340,223 
2019-03-01
4.0
12
3
 1,198,545 
 68,345 
2018-09-01
2.0
4
2
 61,020,567 
 61,698 

Amneal Pharmaceuticals, Notable Stakeholders

An Amneal Pharmaceuticals, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Amneal Pharmaceuticals, often face trade-offs trying to please all of them. Amneal Pharmaceuticals,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Amneal Pharmaceuticals,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Chintu PatelCo-Chief Executive Officer, Co-Founder, DirectorProfile
Chintu RPhCoCEO CoFounderProfile
Chirag PatelPresident, Co-Chief Executive Officer, Co-Founder, DirectorProfile
Paul MeisterIndependent Chairman of the BoardProfile
Sanjay JainPresident OperationsProfile
Anastasios KonidarisChief Financial Officer, Executive Vice PresidentProfile
Nikita ShahChief Human Resource Officer, Executive Vice President, Strategic Planning OfficerProfile
Andrew BoyerExecutive Vice President, Chief Commercial Officer - GenericsProfile
Stephen ManzanoSenior Vice President, General Counsel and Corporate SecretaryProfile
Joseph GreerSenior Vice President - Global Quality ManagementProfile
Joseph TodiscoExecutive Vice President, Chief Commercial Officer - SpecialtyProfile
Gautam PatelDirectorProfile
Ted NarkIndependent DirectorProfile
Emily AlvaIndependent DirectorProfile
John KielyIndependent DirectorProfile
Pranav MehtaSenior ManagementProfile
Jason EsqChief VPProfile
Jeffrey GeorgeIndependent DirectorProfile
Shlomo YanaiIndependent DirectorProfile
Nikunj PatelHead LtdProfile
Gregory SgammatoSenior DevelopmentProfile
Sanjiv PatelVP OperationsProfile
Anthony DiMeoDirector RelationsProfile
Jason DalySenior Vice President Chief Legal Officer and Corporate SecretaryProfile
Apurva SarafSenior Vice President - Corporate DevelopmentProfile
RPh RPhCoCEO CoFounderProfile
J BuchiIndependent DirectorProfile

About Amneal Pharmaceuticals, Management Performance

The success or failure of an entity such as Amneal Pharmaceuticals, often depends on how effective the management is. Amneal Pharmaceuticals, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Amneal management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Amneal management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.04)(0.04)
Return On Capital Employed 0.08  0.12 
Return On Assets(0.02)(0.02)
Return On Equity(4.25)(4.03)
Please note, the imprecision that can be found in Amneal Pharmaceuticals,'s accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Amneal Pharmaceuticals, Class. Check Amneal Pharmaceuticals,'s Beneish M Score to see the likelihood of Amneal Pharmaceuticals,'s management manipulating its earnings.

Amneal Pharmaceuticals, Workforce Analysis

Traditionally, organizations such as Amneal Pharmaceuticals, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Amneal Pharmaceuticals, within its industry.

Amneal Pharmaceuticals, Manpower Efficiency

Return on Amneal Pharmaceuticals, Manpower

Revenue Per Employee304.9K
Revenue Per Executive88.7M
Net Loss Per Employee6.2K
Net Loss Per Executive1.8M
Working Capital Per Employee67.7K
Working Capital Per Executive19.7M

Additional Tools for Amneal Stock Analysis

When running Amneal Pharmaceuticals,'s price analysis, check to measure Amneal Pharmaceuticals,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amneal Pharmaceuticals, is operating at the current time. Most of Amneal Pharmaceuticals,'s value examination focuses on studying past and present price action to predict the probability of Amneal Pharmaceuticals,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amneal Pharmaceuticals,'s price. Additionally, you may evaluate how the addition of Amneal Pharmaceuticals, to your portfolios can decrease your overall portfolio volatility.